20S Proteasome-IN-2
Modify Date: 2024-01-15 19:06:07
20S Proteasome-IN-2 structure
|
Common Name | 20S Proteasome-IN-2 | ||
|---|---|---|---|---|
| CAS Number | 2028300-31-2 | Molecular Weight | 620.76 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C30H44N4O8S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of 20S Proteasome-IN-220S Proteasome-IN-2 is a human 20S proteasome inhibitor. 20S Proteasome-IN-2 shows high selectivity to its β5 subunit with the IC50 of 0.18 μM. 20S Proteasome-IN-2 displays anti-proliferative effect in vitro and in vivo, and arrests cell cycle at G2/M[1]. |
| Name | 20S Proteasome-IN-2 |
|---|
| Description | 20S Proteasome-IN-2 is a human 20S proteasome inhibitor. 20S Proteasome-IN-2 shows high selectivity to its β5 subunit with the IC50 of 0.18 μM. 20S Proteasome-IN-2 displays anti-proliferative effect in vitro and in vivo, and arrests cell cycle at G2/M[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 0.18 μM (β5 subunit of 20S Proteasome) |
| In Vitro | 20S Proteasome-IN-2 (compoun 11m) inhibits 20S proteasome by forming no irreversible covalent modification on it[1]. 20S Proteasome-IN-2 (compoun 11m) (1.56, 3.13, 6.25, 12.5, and 25 μM) shows high binding affinity with purified human 20S proteasome, the equilibrium dissociation constants is 4.8 μM[1]. 20S Proteasome-IN-2 (compoun 11m) (0-1.5 μM; 24 hours) inhibits tumor cells in a low concerntration with IC50 values of 0.88, 0.77, 0.67, 0.73, 1.3, 0.57, and 0.28 μM for A375, BGC-823, Hela, HT-29, A549, PCM1E8, HCT-116, resepectively[1]. 20S Proteasome-IN-2 (compoun 11m) (0-1.5 μM; 24 hours) arrests the cell cycle at G2/M[1]. Cell Cycle Analysis[1] Cell Line: Human colorectal cancer cell line HCT-116 cells Concentration: 1 μM Incubation Time: 24 hours Result: Arrested the cell cycle at G2/M. |
| In Vivo | 20S Proteasome-IN-2 (compoun 11m) is (i.v.; 5 mg/kg; single injection) rapidly cleared from the plasma with an average terminal plasma half-life of 14 min, thus it exhibits extensive tissue permeability and low clearance rate (CL) of 2.0 L/h/k, and is largely eliminated extrahepatically[1]. 20S Proteasome-IN-2 (compoun 11m) (i.v.; 10 mg/kg; twice one week; 4 weeks) shows antitumor efficacy combat solid tumors[1]. Pharmacokinetic parameters of 20S Proteasome-IN-2 (compoun 11m)[1] Administrations Cmax (μg/L) AUC0-t (μg/L•h) T1/2 (min) MRT (min) CL (L/h/kg) Vss (L/kg) iv, 5 mg/kg 2007 680 13.83 20.20 2.0 0.66 Animal Model: HCT-116 cell xenograft nude mice model[1] Dosage: 10 mg/kg Administration: Intravenous injection; twice weekly for consecutive four weeks Result: Inhibited tumor growth in vivo and was well tolerated. |
| References |
| Molecular Formula | C30H44N4O8S |
|---|---|
| Molecular Weight | 620.76 |